Related references
Note: Only part of the references are listed.Levodopa-induced dyskinesia: a historical review of Parkinson's disease, dopamine, and modern advancements in research and treatment
Carissa A. Hansen et al.
JOURNAL OF NEUROLOGY (2022)
Targeting alpha-synuclein via the immune system in Parkinson's disease: Current vaccine therapies
Sheila M. Fleming et al.
NEUROPHARMACOLOGY (2022)
Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease
Stephen Salloway et al.
JAMA NEUROLOGY (2022)
Editorial: Excitotoxicity Turns 50. The Death That Never Dies
Alberto Granzotto et al.
FRONTIERS IN NEUROSCIENCE (2022)
Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease 2019
Emma Nichols et al.
LANCET PUBLIC HEALTH (2022)
Pharmacokinetics and Comparative Bioavailability of Apomorphine Sublingual Film and Subcutaneous Apomorphine Formulations in Patients with Parkinson's Disease and OFF'' Episodes: Results of a Randomized, Three-Way Crossover, Open-Label Study
Felix Agbo et al.
NEUROLOGY AND THERAPY (2021)
NM101 Phase III study of NE3107 in Alzheimer's: rationale, design and therapeutic modulation of neuroinflammation and insulin resistance
Christopher L. Reading et al.
NEURODEGENERATIVE DISEASE MANAGEMENT (2021)
Efficacy of acetylcholinesterase inhibitors in Alzheimer's disease
Gabriella Marucci et al.
NEUROPHARMACOLOGY (2021)
Opicapone (Ongentys): A New COMT Inhibitor for the Treatment of Parkinson's Disease
Erin St Onge et al.
ANNALS OF PHARMACOTHERAPY (2021)
AVP-786 as a promising treatment option for Alzheimer's Disease including agitation
Rita Khoury et al.
EXPERT OPINION ON PHARMACOTHERAPY (2021)
Therapeutic potential of TAK-071, a muscarinic M1 receptor positive allosteric modulator with low cooperativity, for the treatment of cognitive deficits and negative symptoms associated with schizophrenia
Emi Kurimoto et al.
NEUROSCIENCE LETTERS (2021)
Novel targeted therapies for Parkinson's disease
Theodora Ntetsika et al.
MOLECULAR MEDICINE (2021)
Effect of Levetiracetam on Cognition in Patients With Alzheimer Disease With and Without Epileptiform Activity A Randomized Clinical Trial
Keith Vossel et al.
JAMA NEUROLOGY (2021)
A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data
Gennaro Pagano et al.
FRONTIERS IN NEUROLOGY (2021)
Current Status of Clinical Trials on Tau Immunotherapies
Changyi Ji et al.
DRUGS (2021)
Aducanumab: a new phase in therapeutic development for Alzheimer's disease?
Giovanna Lalli et al.
EMBO MOLECULAR MEDICINE (2021)
A technology evaluation of CVT-301 (Inbrija): an inhalable therapy for treatment of Parkinson's disease
Michael M. Lipp et al.
EXPERT OPINION ON DRUG DELIVERY (2021)
An Update on Gene Therapy Approaches for Parkinson's Disease: Restoration of Dopaminergic Function
Amber D. Van Laar et al.
JOURNAL OF PARKINSONS DISEASE (2021)
Approval of Aducanumab for Alzheimer Disease-the FDA's Perspective
Billy Dunn et al.
JAMA INTERNAL MEDICINE (2021)
Current Therapies in Clinical Trials of Parkinson's Disease: A 2021 Update
E. Maruthi Prasad et al.
PHARMACEUTICALS (2021)
A vaccine to prevent initial loss of cognition and eventual Alzheimer's disease in elderly persons
Jeffrey Fessel
ALZHEIMERS & DEMENTIA-TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS (2021)
Extracellular Vesicles for the Diagnosis and Treatment of Parkinson's Disease
Raghavendra Upadhya et al.
AGING AND DISEASE (2021)
Neural regeneration therapies for Alzheimer's and Parkinson's disease-related disorders
Arubala P. Reddy et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2020)
CRISPR System: A High-throughput Toolbox for Research and Treatment of Parkinson's Disease
Fatemeh Safari et al.
CELLULAR AND MOLECULAR NEUROBIOLOGY (2020)
Potent Acetylcholinesterase Inhibitors: Potential Drugs for Alzheimer's Disease
Hulya Akincioglu et al.
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2020)
Clinical Trial Highlights - Infusion Therapies
Neha Prakash et al.
JOURNAL OF PARKINSONS DISEASE (2020)
Cellular backpacks for macrophage immunotherapy
C. Wyatt Shields et al.
SCIENCE ADVANCES (2020)
Classics in Chemical Neuroscience: Pramipexole
Sean M. Wilson et al.
ACS CHEMICAL NEUROSCIENCE (2020)
Current and projected future economic burden of Parkinson's disease in the U.S.
Wenya Yang et al.
NPJ PARKINSONS DISEASE (2020)
Enzymatic protection and biocompatibility screening of enzyme-loaded polymeric nanoparticles for neurotherapeutic applications
Rick Liao et al.
BIOMATERIALS (2020)
Medical Management and Prevention of Motor Complications in Parkinson's Disease
Stephen D. Aradi et al.
NEUROTHERAPEUTICS (2020)
Therapeutic potential and safety considerations for the clinical use of synthetic cannabinoids
Dennis J. Sholler et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2020)
Mesenchymal stem cell-derived exosome: a promising alternative in the therapy of Alzheimer's disease
Mengtian Guo et al.
ALZHEIMERS RESEARCH & THERAPY (2020)
Extracellular Vesicles as Nanotherapeutics for Parkinson's Disease
Loredana Leggio et al.
BIOMOLECULES (2020)
The Discovery of Suvorexant: Lessons Learned That Can Be Applied to Other CNS Drug Development Efforts
Jason M. Uslaner et al.
ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE (2020)
Challenges and translational considerations of mesenchymal stem/stromal cell therapy for Parkinson's disease
Dominika Fricova et al.
NPJ REGENERATIVE MEDICINE (2020)
Size, shape, and flexibility influence nanoparticle transport across brain endothelium under flow
Maksymilian Nowak et al.
BIOENGINEERING & TRANSLATIONAL MEDICINE (2020)
Superoxide dismutase reduces monosodium glutamate-induced injury in an organotypic whole hemisphere brain slice model of excitotoxicity
Rick Liao et al.
JOURNAL OF BIOLOGICAL ENGINEERING (2020)
Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2020
Kevin McFarthing et al.
JOURNAL OF PARKINSONS DISEASE (2020)
Mapping the Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory to the Health Utility Index Mark III
Yin Bun Cheung et al.
QUALITY OF LIFE RESEARCH (2019)
A Close Look at BACE1 Inhibitors for Alzheimer's Disease Treatment
Brati Das et al.
CNS DRUGS (2019)
Emerging therapies in Parkinson disease - repurposed drugs and new approaches
Ahmad Elkouzi et al.
NATURE REVIEWS NEUROLOGY (2019)
Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases
Alberto J. Espay et al.
NEUROLOGY (2019)
Intranasal Administration of Extracellular Vesicles Derived from Human Teeth Stem Cells Improves Motor Symptoms and Normalizes Tyrosine Hydroxylase Expression in the Substantia Nigra and Striatum of the 6-Hydroxydopamine-Treated Rats
Karina Narbute et al.
STEM CELLS TRANSLATIONAL MEDICINE (2019)
Neuro-inflammation and anti-inflammatory treatment options for Alzheimer's disease
Tomris Ozben et al.
CLINICAL BIOCHEMISTRY (2019)
Rotigotine Transdermal Patch: A Review in Parkinson's Disease
James E. Frampton
CNS DRUGS (2019)
Shape effect in active targeting of nanoparticles to inflamed cerebral endothelium under static and flow conditions
A. Da Silva-Candal et al.
JOURNAL OF CONTROLLED RELEASE (2019)
Progress of Pharmacological Approaches in Parkinson's Disease
Kirsten L. Zeuner et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2019)
Non-invasive delivery strategies for biologics
Aaron C. Anselmo et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Transcytosis to Cross the Blood Brain Barrier, New Advancements and Challenges
Victor M. Pulgar
FRONTIERS IN NEUROSCIENCE (2019)
CRISPR/Cas9 Edited sRAGE-MSCs Protect Neuronal Death in Parkinson's Disease Model
Aesuk Lee et al.
INTERNATIONAL JOURNAL OF STEM CELLS (2019)
A phase 1 clinical trial of the sigma-2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer's disease
Michael Grundman et al.
ALZHEIMERS & DEMENTIA-TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS (2019)
Microglia-derived extracellular vesicles in Alzheimer's Disease: A double-edged sword
Teresa Trotta et al.
BIOCHEMICAL PHARMACOLOGY (2018)
The Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog): Modifications and Responsiveness in Pre-Dementia Populations. A Narrative Review
Jacqueline K. Kueper et al.
JOURNAL OF ALZHEIMERS DISEASE (2018)
Small intestinal bacterial overgrowth in Parkinson's disease: Tribulations of a trial
Joaquin A. Vizcarra et al.
PARKINSONISM & RELATED DISORDERS (2018)
Safety, tolerability and immunogenicity of an active anti-Aβ40 vaccine (ABvac40) in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase I trial
Ana-Maria Lacosta et al.
ALZHEIMERS RESEARCH & THERAPY (2018)
CRISPR/Cas9 Mediated Disruption of the Swedish APP Allele as a Therapeutic Approach for Early-Onset Alzheimer's Disease
Bence Gyorgy et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2018)
Serotonergic dysregulation is linked to sleep problems in Parkinson's disease
Heather Wilson et al.
NEUROIMAGE-CLINICAL (2018)
Alzheimer's disease hypothesis and related therapies
Xiaoguang Du et al.
TRANSLATIONAL NEURODEGENERATION (2018)
Amantadine Extended-Release (GOCOVRI™): A Review in Levodopa-Induced Dyskinesia in Parkinson's Disease
Julia Paik et al.
CNS DRUGS (2018)
THE AMYLOID HYPOTHESIS ON TRAIL
Simon Makin
NATURE (2018)
The burden of Parkinson's disease: a worldwide perspective
Walter A. Rocca
LANCET NEUROLOGY (2018)
Systems-level thinking for nanoparticle-mediated therapeutic delivery to neurological diseases
Chad Curtis et al.
WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY (2017)
Why do trials for Alzheimer's disease drugs keep failing? A discontinued drug perspective for 2010-2015
Dev Mehta et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2017)
Mesenchymal stem cell-derived extracellular vesicles: a glimmer of hope in treating Alzheimer's disease
Lee Chuen Liew et al.
INTERNATIONAL IMMUNOLOGY (2017)
Comprehensive study of the drug delivery properties of poly(L-lactide)-poly (ethylene glycol) nanoparticles in rats and tumor-bearing mice
Vladimir Shalgunov et al.
JOURNAL OF CONTROLLED RELEASE (2017)
Antioxidants in Central Nervous System Diseases: Preclinical Promise and Translational Challenges
Chandrashekhar D. Kamat et al.
JOURNAL OF ALZHEIMERS DISEASE (2017)
Focus on Extracellular Vesicles: Exosomes and Their Role in Protein Trafficking and Biomarker Potential in Alzheimer's and Parkinson's Disease
Laura J. Vella et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)
Mitochondrial dysfunction in Parkinson's disease
Anindita Bose et al.
JOURNAL OF NEUROCHEMISTRY (2016)
The antibody aducanumab reduces Aβ plaques in Alzheimer's disease
Jeff Sevigny et al.
NATURE (2016)
Vitamin E in aging persons with Down syndrome: A randomized, placebo-controlled clinical trial
Mary Sano et al.
NEUROLOGY (2016)
Parkinson's Disease: Update on Medication Management
Ann Kriebel-Gasparro
JNP-JOURNAL FOR NURSE PRACTITIONERS (2016)
Monocyte Trafficking, Engraftment, and Delivery of Nanoparticles and an Exogenous Gene into the Acutely Inflamed Brain Tissue - Evaluations on Monocyte-Based Delivery System for the Central Nervous System
Hsin-I Tong et al.
PLOS ONE (2016)
Nanoparticle transport across the blood brain barrier
Andreas M. Grabrucker et al.
TISSUE BARRIERS (2016)
Targeting Receptor-Mediated Transport for Delivery of Biologics Across the Blood-Brain Barrier
Jason M. Lajoie et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 55 (2015)
Catechol-O-Methyltransferase Inhibitors in Parkinson's Disease
Thomas Mueller
DRUGS (2015)
Alzheimer's disease vaccine development: A new strategy focusing on immune modulation
Dante J. Marciani
JOURNAL OF NEUROIMMUNOLOGY (2015)
Neuroinflammation in Alzheimer's disease
Michael T. Heneka et al.
LANCET NEUROLOGY (2015)
The case for rejecting the amyloid cascade hypothesis
Karl Herrup
NATURE NEUROSCIENCE (2015)
Immune attack: the role of inflammation in Alzheimer disease
Frank L. Heppner et al.
NATURE REVIEWS NEUROSCIENCE (2015)
Compliance with Results Reporting at ClinicalTrials.gov
Monique L. Anderson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Neuroinflammation in Parkinson's disease and its potential as therapeutic target
Qinqin Wang et al.
TRANSLATIONAL NEURODEGENERATION (2015)
Apoptosis in Alzheimer's Disease: An Understanding of the Physiology, Pathology and Therapeutic Avenues
M. Obulesu et al.
NEUROCHEMICAL RESEARCH (2014)
The A4 Study: Stopping AD Before Symptoms Begin?
Reisa A. Sperling et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Is dopamine involved in Alzheimer's disease?
Alessandro Martorana et al.
FRONTIERS IN AGING NEUROSCIENCE (2014)
Amyloid-β and Tau The Trigger and Bullet in Alzheimer Disease Pathogenesis
George S. Bloom
JAMA NEUROLOGY (2014)
Amyloid β, Glutamate, Excitotoxicity in Alzheimer's Disease: Are We on the Right Track?
Zaira Esposito et al.
CNS NEUROSCIENCE & THERAPEUTICS (2013)
N-Methyl D-Aspartate (NMDA) Receptor Antagonists and Memantine Treatment for Alzheimer’s Disease, Vascular Dementia and Parkinson’s Disease
David Olivares et al.
Current Alzheimer Research (2013)
Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences
Nicole Exner et al.
EMBO JOURNAL (2012)
Antioxidant Therapies for Alzheimer's Disease
Ye Feng et al.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2012)
A Dense Poly(Ethylene Glycol) Coating Improves Penetration of Large Polymeric Nanoparticles Within Brain Tissue
Elizabeth A. Nance et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Genetics of Parkinson's Disease
Christine Klein et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2012)
Nano-Advantage in Enhanced Drug Delivery with Biodegradable Nanoparticles: Contribution of Reduced Clearance
Rajendra S. Kadam et al.
DRUG METABOLISM AND DISPOSITION (2012)
The Dynamics of Cortical and Hippocampal Atrophy in Alzheimer Disease
Mert R. Sabuncu et al.
ARCHIVES OF NEUROLOGY (2011)
Neuroinflammation in Parkinson's disease
Etienne C. Hirsch et al.
PARKINSONISM & RELATED DISORDERS (2011)
Levetiracetam in the treatment of epilepsy
Bassel Abou-Khalil
Neuropsychiatric Disease and Treatment (2011)
Mitochondria and Antioxidant Targeted Therapeutic Strategies for Alzheimer's Disease
Magali Dumont et al.
JOURNAL OF ALZHEIMERS DISEASE (2010)
Comparison of Orally Dissolving Carbidopa/Levodopa (Parcopa) to Conventional Oral Carbidopa/Levodopa: A Single-Dose, Double-Blind, Double-Dummy, Placebo-Controlled, Crossover Trial
William G. Ondo et al.
MOVEMENT DISORDERS (2010)
Intracellular and extracellular tau
Jesus Avila
FRONTIERS IN NEUROSCIENCE (2010)
Begacestat (GSI-953): A Novel, Selective Thiophene Sulfonamide Inhibitor of Amyloid Precursor Protein γ-Secretase for the Treatment of Alzheimer's Disease
Robert L. Martone et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2009)
Is Parkinson's disease a prion disorder?
C. Warren Olanow et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
No advantage of Aβ42-lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studies
C. A. Szekely et al.
NEUROLOGY (2008)
Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis
Claire Henchcliffe et al.
NATURE CLINICAL PRACTICE NEUROLOGY (2008)
Monoamine oxidase-B inhibition in the treatment of Parkinson's disease
Hubert H. Fernandez et al.
PHARMACOTHERAPY (2007)
Blood-brain barrier delivery
William M. Pardridge
DRUG DISCOVERY TODAY (2007)
Expanding insights of mitochondrial dysfunction in Parkinson's disease
PM Abou-Sleiman et al.
NATURE REVIEWS NEUROSCIENCE (2006)
Parkinson's disease α-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death
LJ Martin et al.
JOURNAL OF NEUROSCIENCE (2006)
The chemical biology of clinically tolerated NMDA receptor antagonists
Huei-Sheng Vincent Chen et al.
JOURNAL OF NEUROCHEMISTRY (2006)
Memantine - A review of its use in Alzheimer's disease
Dean M. Robinson et al.
DRUGS (2006)
A randomized, controlled trial of doxycycline and rifampin for patients with Alzheimer's disease
MB Loeb et al.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2004)
Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease
MR Hynd et al.
NEUROCHEMISTRY INTERNATIONAL (2004)
Blood-brain barrier efflux transport
PL Golden et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2003)
Excitotoxic and excitoprotective mechanisms - Abundant targets for the prevention and treatment of neurodegenerative disorders
MP Mattson
NEUROMOLECULAR MEDICINE (2003)
β-amyloid-induced synthesis of the ganglioside Gd3 is a requisite for cell cycle reactivation and apoptosis in neurons
A Copani et al.
JOURNAL OF NEUROSCIENCE (2002)
Mechanisms of the effects of exogenous levodopa on the dopamine-denervated striatum
A Lopez et al.
NEUROSCIENCE (2001)
Costimulatory effects of interferon-γ and interleukin-1β or tumor necrosis factor α on the synthesis of aβ1-40 and aβ1-42 by human astrocytes
I Blasko et al.
NEUROBIOLOGY OF DISEASE (2000)
Can the cognitive enhancing effects of Ginkgo biloba be explained by its pharmacology?
P Nathan
MEDICAL HYPOTHESES (2000)
Inflammation and Alzheimer's disease
H Akiyama et al.
NEUROBIOLOGY OF AGING (2000)
Oxidative stress and Alzheimer disease
Y Christen
AMERICAN JOURNAL OF CLINICAL NUTRITION (2000)
Share Paper
